Lanreotide Shot

Inflammation is a defensive response to harmful stimuli. However, persistent chronic inflammation or excessive inflammatory reactions can damage tissues and organs, leading to various inflammation‑related diseases such as acute lung injury, chronic pancreatitis, and inflammatory bowel disease. These conditions severely impair quality of life and can even be life‑threatening.

Traditional anti‑inflammatory therapies rely mainly on glucocorticoids and nonsteroidal anti‑inflammatory drugs. Although they rapidly relieve inflammation, long‑term use often causes adverse reactions, and some patients show poor response.

First, the injection specifically binds to somatostatin receptors (mainly subtypes 2, 3, and 5) on various cell surfaces, suppressing the activation of inflammatory cells including macrophages and neutrophils. It reduces the secretion of pro‑inflammatory mediators such as tumor necrosis factor‑α (TNF‑α), interleukin‑6 (IL‑6), and interleukin‑1β (IL‑1β), while promoting the expression of anti‑inflammatory mediators including interleukin‑10 (IL‑10). This restores the balance between pro‑ and anti‑inflammatory responses, thereby reducing inflammatory infiltration and tissue damage.

Second, studies confirm that it effectively inhibits lipopolysaccharide (LPS)‑induced activation of inflammatory signaling pathways, including the mitogen‑activated protein kinase (MAPK) pathway and the signal transducer and activator of transcription (STAT) pathway. Specifically, it suppresses the activation of myosin light chain 2 (MLC2), cofilin, extracellular signal‑regulated kinase 1/2 (ERK1/2), STAT1, STAT3, and p38, blocking the cascade amplification of inflammation and reducing tissue edema and injury.

Main Clinical Application Scenarios

Currently, the clinical use of Lanreotide Shot in anti‑inflammatory therapy is focused on chronic inflammation and infection‑related inflammatory diseases, especially for patients requiring long‑term treatment, poor tolerance, or inadequate response to conventional anti‑inflammatory drugs. Its long‑acting sustained‑release formulation significantly improves convenience and adherence.

Its application is prominent in acute lung injury (ALI) / acute respiratory distress syndrome (ARDS).ALI is often caused by infection, trauma, or intoxication, characterized by inflammatory infiltration, increased capillary permeability, and pulmonary edema, with high clinical mortality.Animal and clinical studies show that it effectively alleviates LPS‑induced pulmonary edema and inflammation, inhibits inflammatory cell infiltration in lung tissue, reduces pro‑inflammatory mediator secretion, improves gas exchange, and reduces the severity of lung injury.

In patients with severe infection or sepsis‑induced ALI, combination therapy with it on the basis of standard anti‑infective and mechanical ventilation treatment can assist in reducing pulmonary inflammation, shorten mechanical ventilation time, and improve prognosis. Its once‑every‑4‑weeks dosing schedule reduces the burden in critically ill patients and lowers the risk of injection‑related adverse reactions.

It is also well‑established in chronic pancreatitis.Chronic pancreatitis is a progressive inflammatory disorder characterized by pancreatic fibrosis and inflammatory cell infiltration, manifesting as recurrent abdominal pain and dyspepsia, which may progress to pancreatic insufficiency.As a somatostatin analog, it inhibits exocrine pancreatic function and enzyme secretion, suppresses local inflammation, reduces inflammatory infiltration, slows fibrosis, and relieves abdominal pain and bloating.Compared with short‑acting somatostatin analogs, it requires no daily injections; once‑every‑4‑week administration maintains stable anti‑inflammatory effects.

It is especially suitable for long‑term maintenance therapy, effectively reducing symptom recurrence and improving quality of life while avoiding the pain and inconvenience of frequent injections.

Furthermore, it has adjuvant therapeutic value in inflammatory bowel disease (Crohn's disease, ulcerative colitis), chronic hepatitis, and rheumatoid arthritis.In inflammatory bowel disease, it suppresses intestinal mucosal inflammation, reduces congestion, edema, and ulceration, and relieves diarrhea, abdominal pain, and mucopurulent bloody stools. It is particularly useful for patients with concurrent endocrine disorders, as it simultaneously regulates hormone levels and inflammation.In rheumatoid arthritis, it helps inhibit synovial inflammation, reduce swelling, pain, and deformity, and slow disease progression, though it remains an adjuvant used in combination with conventional antirheumatic drugs.

Bacterial infections are common in clinical practice, especially multidrug‑resistant and chronic bacterial infections. Conventional antimicrobials show limited efficacy, and long‑term use often leads to drug resistance, intestinal dysbiosis, and other adverse effects, severely compromising outcomes.

Although not a direct antimicrobial agent, it, as a somatostatin analog, plays an important adjunctive role in antimicrobial therapy by modulating host immune function, inhibiting bacterial colonization and proliferation, and enhancing the efficacy of antimicrobial drugs. It is particularly valuable for chronic and multidrug‑resistant bacterial infections.Combined with its long‑acting sustained‑release formulation, it can reduce the frequency and dosage of antimicrobials, lower the risk of resistance, and provide a novel adjuvant strategy for infection management.

First, by binding to somatostatin receptors on immune cells, it modulates immune function: it enhances the phagocytic and bactericidal activity of macrophages and neutrophils, promotes bacterial clearance, and inhibits excessive immune cell activation to reduce inflammatory tissue damage during infection.

Second, it suppresses excessive secretion from mucosal epithelial cells, reduces mucus production, and decreases bacterial colonization on mucosal surfaces - especially in the gastrointestinal and respiratory tracts. This lowers the risk of recurrent infection. It also helps restore intestinal microbial balance, inhibiting pathogenic growth while promoting beneficial flora, thereby reducing systemic infection caused by bacterial translocation, particularly in patients with intestinal dysbiosis due to long‑term antimicrobial use.

Furthermore, studies show that it enhances susceptibility to antimicrobial agents and reduces the emergence of multidrug resistance.It inhibits bacterial efflux pump systems, reducing antimicrobial extrusion and increasing intracellular drug concentration, thereby strengthening inhibitory or bactericidal effects.It also suppresses bacterial biofilm formation - a major contributor to antimicrobial resistance and recurrent infection. Disrupting biofilms improves antimicrobial efficacy and reduces recurrence rates.

Compared with conventional adjuvant agents, it offers long duration, convenient dosing, and no additional antimicrobial‑related adverse reactions, representing significant clinical advantages.

Main Clinical Application Scenarios

Lanreotide Shot is used as adjuvant therapy in the antimicrobial field, primarily for patients with chronic bacterial infection, multidrug‑resistant infection, or high recurrence risk. Its long‑acting formulation reduces antimicrobial dosing frequency, improves adherence, and improves prognosis, especially for those requiring long‑term adjuvant therapy.

It is most widely used as adjunctive treatment for chronic bacterial infections, including chronic bronchitis with bacterial infection, chronic pyelonephritis, and chronic biliary tract infection.Patients with chronic bronchitis and recurrent bacterial infections often develop resistance to frequent antimicrobial courses.

It enhances immune function, inhibits respiratory bacterial colonization, assists antimicrobials in pathogen clearance, reduces recurrence, and alleviates respiratory inflammation and cough.Clinically, adding it 90 mg subcutaneously every 4 weeks to standard antimicrobial therapy significantly prolongs infection‑free intervals, reduces total antimicrobial consumption, and improves quality of life.

It has important value in the adjunctive treatment of multidrug‑resistant bacterial infections (e.g., methicillin‑resistant Staphylococcus aureus, carbapenem‑resistant Enterobacterales), which are difficult to treat with conventional agents.It improves antimicrobial susceptibility and inhibits biofilm formation, increasing treatment success.In critically ill patients with multidrug‑resistant pneumonia or bloodstream infection, combining it 120 mg every 4 weeks with effective antimicrobials enhances bactericidal effects, shortens infection control time, reduces mortality, and lowers the risk of further resistance development.